Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: OraSure develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. Key product lines include the OraQuick rapid HIV and Hepatitis C (HCV) tests, the Intercept drug testing system, and cryosurgical systems for skin lesion removal. The company operates within a single reportable segment and sells products globally to clinical laboratories, hospitals, public health organizations, and retail markets.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenues | $75.0 million | $77.0 million |
| Gross Profit | $47.4 million | $47.1 million |
| Gross Margin | 63% | 61% |
| Operating Loss | $(3.4) million | $(8.8) million |
| Net Loss | $(3.5) million | $(7.8) million |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.17) |
| Cash Flow from Operations | $3.9 million | $(0.3) million |
| Cash, Cash Equivalents & Short-Term Investments | $75.7 million | $79.7 million |
| Working Capital | $77.8 million | $89.4 million |
| Total Debt (Current Portion) | $7.8 million | $0.5 million |
| Accumulated Deficit | $(138.6) million | $(135.1) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3% to $75.0 million. This was driven by a 9% decline in infectious disease testing sales (primarily OraQuick HIV) and a 3% decline in substance abuse testing. These decreases were partially offset by a 10% increase in cryosurgical systems sales and a 105% increase in licensing and product development revenues.
- Improved Profitability: The net loss narrowed significantly from $7.8 million in 2009 to $3.5 million in 2010. The 2009 loss included a $3.0 million impairment charge for HCV patents and a $1.5 million litigation settlement expense, neither of which occurred in 2010.
- Operating Cash Flow: Cash provided by operating activities improved to $3.9 million in 2010 from a use of $0.3 million in 2009, driven by non-cash stock-based compensation and depreciation offsetting the net loss.
- Debt Classification: The entire remaining balance of the company's credit facility ($7.8 million) was reclassified as a current liability in 2010 due to its maturity date in June 2011.
Guidance, Outlook, and Risks
- Product Developments:
- OraQuick HIV OTC: The company received FDA approval for an Investigational Device Exemption (IDE) in late 2010 to begin the final phase of clinical testing for an over-the-counter HIV test. Results are expected in 2011.
- OraQuick HCV: FDA approval was received for venous and finger-stick blood specimens. The company is pursuing an oral fluid claim and a CLIA waiver.
- Substance Abuse: Collaboration with Roche Diagnostics resulted in FDA clearances for high-throughput oral fluid drug assays (PCP, opiates, cocaine, methamphetamines) in early 2011, with commercial launch expected later in 2011.
- QuickFlu: The company acquired distribution rights for a rapid flu test (OraSure QuickFlu) in early 2011.
- Strategic Shifts: The company ceased selling its U.S. OTC cryosurgical product ("Freeze 'n Clear") at the end of 2010 due to limited revenues and funding constraints.
- Liquidity and Debt: The company has a $10 million credit facility with Comerica Bank maturing in June 2011. As of December 31, 2010, no borrowings were available. Management is evaluating refinancing options.
- Risks:
- Regulatory: Delays or failures in obtaining FDA approvals for the OTC HIV test or oral fluid HCV claims could significantly impact future revenues.
- Competition: Intense competition in HIV testing, particularly from lower-priced blood-based tests, and "home-brew" assays in drug testing.
- Supply Chain: Reliance on sole-source suppliers for critical components (e.g., HIV antigen, nitrocellulose).
- Profitability: The company has a history of losses and an accumulated deficit of $138.6 million; future profitability is not assured.
Investor Verification Checklist
- Debt Refinancing: Verify the status of the $7.8 million credit facility maturing in June 2011 and the company's ability to refinance or repay it.
- OTC HIV Approval: Monitor the progress of the final clinical phase for the OraQuick HIV OTC test and the timeline for FDA submission.
- HCV Oral Fluid Claim: Track the status of the FDA filing for the oral fluid claim for the OraQuick HCV test, which has been delayed pending additional testing.
- Roche Collaboration: Assess the commercial launch timeline and initial sales performance of the new high-throughput oral fluid drug assays with Roche Diagnostics.
- Valuation Allowance: Note the full valuation allowance against net deferred tax assets ($28.8 million), meaning the company cannot currently utilize its $50.4 million in net operating loss carryforwards to offset taxes.